Caffeine disposition in obesity
- PMID: 4027137
- PMCID: PMC1400629
- DOI: 10.1111/j.1365-2125.1985.tb02799.x
Caffeine disposition in obesity
Abstract
Caffeine pharmacokinetics were studied in 16 obese (mean +/- s.e. mean body weight; 110 +/- 8 kg; % ideal body weight (IBW); 186 +/- 14%) and 23 normal body weight (64 +/- 3 kg; 103 +/- 3% IBW) subjects. Eight obese and four control subjects were cigarette smokers. After abstaining from caffeine for 48 h and an overnight fast, each subject ingested 162 mg caffeine orally. Concentrations of caffeine were measured in plasma samples obtained during the 24 h following the dose and pharmacokinetic variables were determined. The apparent volume of distribution was increased markedly in obese subjects (69.9 +/- 5.9 vs 43.6 +/- 2.8 l; P less than 0.001) in the absence of any change in oral clearance (135 +/- 14-obese vs 112 +/- 12 ml/min; NS), resulting in a trend toward increased elimination half-life (7.05 +/- 1.08-obese vs 5.40 +/- 0.40 h; NS). Apparent volume of distribution correlated well with percent IBW (r = 0.65; P less than 0.001). Caffeine clearance, suggested as a measure of in vivo cytochrome P-448 activity in humans, was not altered in obesity. In contrast, the extent of caffeine distribution increased in direct relation to body weight. If caffeine is used therapeutically, the loading dose should be calculated as a function of total body weight. Since clearance of caffeine is not related to body weight, these data indicate that a chronic dosing regimen to maintain a given plasma caffeine concentration should not be altered due to obesity.
Similar articles
-
Obesity effects on nitrazepam disposition.Br J Clin Pharmacol. 1986 Nov;22(5):551-7. doi: 10.1111/j.1365-2125.1986.tb02934.x. Br J Clin Pharmacol. 1986. PMID: 3790401 Free PMC article.
-
Digoxin disposition in obesity: clinical pharmacokinetic investigation.Am Heart J. 1981 Oct;102(4):740-4. doi: 10.1016/0002-8703(81)90100-9. Am Heart J. 1981. PMID: 7282520
-
Caffeine pharmacokinetics in obesity and following significant weight reduction.Int J Obes Relat Metab Disord. 1995 Apr;19(4):234-9. Int J Obes Relat Metab Disord. 1995. PMID: 7627246 Clinical Trial.
-
Clinical pharmacokinetics of drugs in obesity. An update.Clin Pharmacokinet. 1993 Aug;25(2):103-14. doi: 10.2165/00003088-199325020-00003. Clin Pharmacokinet. 1993. PMID: 8403734 Review.
-
Effect of obesity on the pharmacokinetics of drugs in humans.Clin Pharmacokinet. 2010;49(2):71-87. doi: 10.2165/11318100-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20067334 Review.
Cited by
-
Pharmacokinetics of Caffeine: A Systematic Analysis of Reported Data for Application in Metabolic Phenotyping and Liver Function Testing.Front Pharmacol. 2022 Feb 25;12:752826. doi: 10.3389/fphar.2021.752826. eCollection 2021. Front Pharmacol. 2022. PMID: 35280254 Free PMC article. Review.
-
The Influence of Obesity on the Pharmacokinetics of Dioxin in Mice: An Assessment Using Classical and PBPK Modeling.Toxicol Sci. 2018 Jul 1;164(1):218-228. doi: 10.1093/toxsci/kfy078. Toxicol Sci. 2018. PMID: 29596651 Free PMC article.
-
Caffeine intake reduces sedentary time and increases physical activity predisposition in obese police officers.Braz J Med Biol Res. 2021 Sep 20;54(11):e11556. doi: 10.1590/1414-431X2021e11556. eCollection 2021. Braz J Med Biol Res. 2021. PMID: 34550274 Free PMC article.
-
The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s: a systematic review of current evidence on human studies.Eur J Nutr. 2021 Sep;60(6):2905-2921. doi: 10.1007/s00394-020-02421-y. Epub 2020 Nov 3. Eur J Nutr. 2021. PMID: 33141242 Review.
-
Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution.Cancer Chemother Pharmacol. 1989;25(2):139-42. doi: 10.1007/BF00692355. Cancer Chemother Pharmacol. 1989. PMID: 2557169
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous